Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. Mechanisms of acquired resistance are...

Descripción completa

Detalles Bibliográficos
Autores principales: Klempner, Samuel J, Mehta, Pareen, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122/
https://www.ncbi.nlm.nih.gov/pubmed/29255376
http://dx.doi.org/10.2147/LCTT.S147129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122/
https://www.ncbi.nlm.nih.gov/pubmed/29255376
http://dx.doi.org/10.2147/LCTT.S147129

Ejemplares similares